[1] S Allouch, A Malki, A Allouch et al. High-risk HPV oncoproteins and PD-1/PD-L1 interplay in human cervical cancer: recent evidence and future directions. Frontiers in Oncology, 10, 914(2020).

[2] He HUANG, Jihong LIU. Standardization of postoperative adjuvant treatment for cervical cancer. Chinese Journal of Practical Gynecology and Obstetrics, 37, 51-54(2021).

[3] W Small, L K Mell, P Anderson et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. International Journal of Radiation Oncology, 71, 428-434(2008).

[4] Saixia LIN. Application of contrast agent in computed tomography of cervical cancer. Strait Pharmaceutical Journal, 19, 85-86(2007).

[5] E M Quan, X Q Li, Y P Li et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. International Journal of Radiation Oncology, 83, 1169-1178(2012).

[6] Lihong LIN, Yu GUO. Preliminary study on clinical application of silver clip labeling method in target area delineation of intensity modulated radiotherapy. Journal of Medical Information, 27, 560-561(2014).

[7] Lijuan HU, Jing ZHANG, Min ZHOU et al. Dosimetric study of volumetric intensity-modulated arc therapy and intensity modulated radiation therapy in postoperative radiotherapy for cervical cancer with ovarian preservation. The Practical Journal of Cancer, 37, 1851-1854(2022).

[8] Junfeng GAO. Dosimetric comparison of conformal, intensity-modulated and conventional pelvic radiotherapy plans in posthysterectomy cervical cancer patients, 11-15(2011).

[9] H J Kim, A R Chang, Y K Park et al. Dosimetric effect of CT contrast agent in CyberKnife treatment plans. Radiation Oncology, 8, 244(2013).

[10] J W Denham, M Hauer-Jensen. The radiotherapeutic injury: a complex 'wound'. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 63, 129-145(2002).

[11] Wendong GU, Qilin LI, Min GAO et al. Impact of oral contrast agent for assisting in outlining small bowel on pelvic VMAT dose in patients with cervical cancer. Chinese Journal of Radiation Oncology, 23, 472-474(2014).

[12] U Ramm, M Damrau, S Mose et al. Influence of CT contrast agents on dose calculations in a 3D treatment planning system. Physics in Medicine and Biology, 46, 2631-2635(2001).

[13] Ruijie YANG, Wenbao WANG, Yue ZHANG et al. Effect of intravenous contrast agent on dose distribution in treatment planning for postoperative whole pelvic radiotherapy of gynecologic cancer. Journal of Practical Oncology, 25, 311-314(2010).